格隆汇8月14日丨根据联交所最新权益披露资料显示，2025年8月8日，泰格医药(03347.HK)获易方达基金管理有限公司在场内以每股均价52.7935港元增持 54.91万股，涉资约2898.89万港元。 增持后，易方达基金管理有限公司最新持股数目为1654.32万股，持股比例由12.99%上升至13.44%。 | 股份代號: | 03347 | | --- | --- | | 上市法國名稱: | 杭州泰格醫藥科技股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 14/07/2025 - 14/08/2025 | | 麦格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 開天 | 股份數目 | | | ( 請參閱上述 * 註 有投票權股 期 (日 / 月 / | | | | | | | | | | 份百分比 年) | | | | | | | | (% | | | ...

Group 1 - E Fund Management Co., Ltd. increased its stake in Tiger Medical (03347) by 549,100 shares at a price of HKD 52.7935 per share, totaling approximately HKD 28.9889 million [1] - After the increase, E Fund's total shareholding in Tiger Medical reached 16.5432 million shares, representing a holding percentage of 13.44% [1]

香港联交所最新数据显示，8月8日，易方达基金管理有限公司增持泰格医药（300347）(03347)54.91万 股，每股作价52.7935港元，总金额约为2898.89万港元。增持后最新持股数目为1654.32万股，持股比例 为13.44%。 ...

Group 1 - The core viewpoint of the news is that Tiger Med (300347) has experienced a stock price increase of 2.95% to 69.0 yuan as of August 13, 2025, with significant trading volume and capital inflow [1] - The company reported total revenue of 1.564 billion yuan for Q1 2025, a year-on-year decrease of 5.79%, and a net profit of 165 million yuan, down 29.61% year-on-year [1] - The company's financial ratios include a current ratio of 1.622, a quick ratio of 1.611, and a debt-to-asset ratio of 16.78% [1] Group 2 - Tiger Med has made investments in 55 companies and participated in 50 bidding projects, indicating active engagement in the market [2] - The company holds 38 trademark registrations and 17 patents, showcasing its focus on intellectual property [2] - Additionally, Tiger Med possesses 45 administrative licenses, reflecting its compliance and operational capabilities [2]

据介绍，Aficare是非洲大陆首个集高端制剂生产、创新药研发及重大疾病解决方案于一体的现代化制药 企业。此次签署合作备忘录后，双方将在多个关键领域展开合作。包括与非洲多国国立医学研究院、国 家医药研究所共建非洲多中心临床研究基地，聚焦抗慢性病(糖尿病、高血脂)、抗癌症、抗病毒等领 域，利用非洲多样化人群临床数据加速全球新药研发。 消息面上，据泰格医药官微消息，近日，泰格医药与Africare BioPharma(简称Africare)正式签署合作备 忘录，双方将在非洲地区临床研究全链条服务能力建设、临床研究数字技术平台搭建、研究中心能力提 升、相关人才培养及政策法规引导和制定等方面展开深入合作。 泰格医药（300347）(03347)涨超3%，截至发稿，涨3.33%，报54.35港元，成交额3831.07万港元。 ...

智通财经APP获悉，泰格医药(03347)涨超3%，截至发稿，涨3.33%，报54.35港元，成交额3831.07万港 元。 消息面上，据泰格医药官微消息，近日，泰格医药与 Africare BioPharma(简称Africare) 正式签署合作备 忘录，双方将在非洲地区临床研究全链条服务能力建设、临床研究数字技术平台搭建、研究中心能力提 升、相关人才培养及政策法规引导和制定等方面展开深入合作。 据介绍，Aficare是非洲大陆首个集高端制剂生产、创新药研发及重大疾病解决方案于一体的现代化制药 企业。此次签署合作备忘录后，双方将在多个关键领域展开合作。包括与非洲多国国立医学研究院、国 家医药研究所共建非洲多中心临床研究基地，聚焦抗慢性病(糖尿病、高血脂)、抗癌症、抗病毒等领 域，利用非洲多样化人群临床数据加速全球新药研发。 ...

Group 1 - The core point of the news is that E Fund Management Co., Ltd. has increased its stake in Tiger Med (03347.HK) by purchasing 66,200 shares at an average price of HKD 53.8841 per share, resulting in a total investment of approximately HKD 3.5671 million [1] - After the purchase, E Fund's total shareholding in Tiger Med reached 14.8183 million shares, increasing its ownership percentage from 11.98% to 12.04% [1]

Group 1 - The core focus of the company is on addressing significant unmet clinical needs and empowering innovative enterprises for pharmaceutical innovation [1] - The event "Shenzhen Stock Exchange · Innovation Forum" for the biopharmaceutical industry was held in Hangzhou on August 5 [1] - The general manager of the company, Cao Xiaochun, emphasized the commitment to supporting the growth of innovative companies [1]

Group 1 - The core viewpoint of the news is that Tiger Medical (300347) has shown a decline in revenue and net profit in its latest quarterly report, indicating potential challenges ahead for the company [1] - As of August 8, 2025, Tiger Medical's stock closed at 65.24 yuan, with a slight increase of 0.88% and a trading volume of 78500 lots, amounting to 507 million yuan [1] - The company's latest quarterly report shows total revenue of 1.564 billion yuan, a year-on-year decrease of 5.79%, and a net profit attributable to shareholders of 165 million yuan, down 29.61% year-on-year [1] Group 2 - The company's non-recurring net profit was reported at 102 million yuan, reflecting a significant year-on-year decrease of 66.23% [1] - The liquidity ratios indicate a current ratio of 1.622 and a quick ratio of 1.611, with a debt-to-asset ratio of 16.78% [1] - Tiger Medical has made investments in 55 companies and participated in 50 bidding projects, showcasing its active engagement in the market [2]

鉴于目前牛市市况，该行预料生物科技融资将有所改善，并相信泰格医药的投资收益将超过其核心业务 的临床服务费。此外，该行预料，泰格医药次季销售呈单位数同比正向增长，而去年首季至今年首季的 五个季度则录同比下跌;另料经营利润率按季有所改变。又预期由次季起，新订单持续按季改善。 智通财经APP获悉，里昂发布研报称，随着2025年上半年中国创新药市场情势好转，泰格医药(03347)股 价年初至今已上涨83%。该行维持对泰格医药2025至2027年的收入及经营溢利预测不变，料收入增长 7%至9%，净利润分别上调31%、30%及30%，目标价由34.2港元上调至62.6港元，维持"跑赢大市"评 级。 ...